招商证券股份有限公司 关于昆山亚香香料股份有限公司 2024 年度募集资金存放和使用情况的核查意见 招商证券股份有限公司（以下简称"招商证券"或"保荐机构"）作为昆山亚香 香料股份有限公司（以下简称"亚香股份"或"公司"）的持续督导机构。根据《证 券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证 券交易所上市公司自律监管指引第 13 号——保荐业务》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》等法律法规的规定，招商证券 对亚香股份在 2024 年度募集资金存放与使用情况进行了审慎核查，核查情况及 核查意见如下： 一、募集资金基本情况 实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意昆山亚香香料股份有限公司首次公开 发行股票注册的批复》（证监许可〔2022〕892 号）核准，并经深圳证券交易所同 意，公司首次向社会公众发行人民币普通股（A 股）股票 2,020.00 万股，每股面 值人民币 1.00 元，发行价格为人民币 35.98 元/股，募集资金总额为人民币 726 ...

RSM 容诚 内部控制审计报告 昆山亚香香料股份有限公司 容诚审字[2025]215Z0234号 容诚会计 百 容诚会计师事务所(特殊普通合伙) 中国 · 北京 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 报告编码:京25YG 目 录 | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | | 内部控制鉴证报告 | | 1-2 | | 2 | 2024 年度内部控制评价报告 | | 1-6 | 内部控制审计报告 容诚审字[2025]215Z0234号 昆山亚香香料股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了昆山亚香香料股份有限公司(以下简称"亚香股份公司")2024年 12 月 31 目的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是亚香 股份公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计 ...

昆山亚香香料股份有限公司 (刘文) 各位股东及股东代表： 作为昆山亚香香料股份有限公司（以下简称"公司"）的独立董事，2024 年度 任职期间，本人严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公 司独立董事规则》等法律、法规和《公司章程》的有关规定，忠实履行独立董事 的职责，谨慎、认真、勤勉地行使公司所赋予独立董事的权利，积极出席公司相 关会议，认真审议各项议案，对公司的相关事项发表了独立意见，较好地维护了 公司和股东特别是中小股东的合法权益。现就本人 2024 年度任职期间履行职责 情况述职如下： 一、独立董事基本情况 刘文，男，1968 年 2 月出生，中国国籍，无境外永久居留权，会计专业大学 本科学历，注册会计师。1995 年至 1996 年，任安徽铜陵市会计师事务所审计员； 曾任台玻长江玻璃有限公司财务经理；曾任苏州勤安会计师事务所（普通合伙） 合伙人；曾任昆山安勤投资咨询有限公司监事；曾任昆山富添投资股份有限公司 副董事长；曾任江苏昆山农村商业银行股份有限公司独立董事；2017 年至今，任 苏州勤安华瑞管理咨询有限公司监事；2022 年 4 月至今，任亚香股份独立董事， 本人未在公司 ...

昆山亚香香料股份有限公司 2024 年度独立董事述职报告 (王俊) 各位股东及股东代表： 作为昆山亚香香料股份有限公司（以下简称"公司"）的独立董事，2024 年度， 本人严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公司独 立董事规则》等法律法规和《公司章程》的有关规定，忠实履行独立董事的职责， 谨慎、认真、勤勉地行使公司所赋予独立董事的权利，积极出席公司相关会议， 认真审议各项议案，对公司的相关事项发表了独立意见，较好地维护了公司和股 东特别是中小股东的合法权益。现就本人 2024 年度履行职责情况述职如下： 一、独立董事基本情况 王俊，男，1967 年 7 月出生，中国国籍，无境外永久居留权，化学专业大学 专科学历，高级工程师。1987 年至 1993 年，任上海黄浦仪器厂技术研发助理工 程师；1994 年至 2000 年，任上海新华香料厂质量监督科科长；2000 年至 2007 年，任滕州悟通香料有限公司董事兼副总经理；2007 年至 2013 年，任北京北大 正元科技有限公司技术总监；2013 年至 2015 年，任四川鼎世生物科技有限公司 总工程师；2015 年至 2018 年，任南 ...

昆山亚香香料股份有限公司 昆山亚香香料股份有限公司 董事会对独立董事独立性评估的专项报告 根据证监会《上市公司独立董事管理办法》、《深圳证券交易所创业板股票上市 规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等要求，昆山亚香香料股份有限公司（以下简称"公司"）董事会，就公司在任 独立董事刘文先生、王俊先生，李群英女士的独立性情况进行评估并出具如下专项意 见： 经核查独立董事刘文先生、王俊先生、李群英女士的任职经历以及签署的相关自 查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，不存在影响独立董事独立性的情况。因此，公司独立董事符合 《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》中对独立董事独立性的相关要求。 董事会 2025 年 4 月 23 日 ...

2024 年度独立董事述职报告 (李群英) 各位股东及股东代表： 作为昆山亚香香料股份有限公司（以下简称"公司"）的独立董事，2024 年 度，本人严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公 司独立董事规则》等法律法规和《公司章程》的有关规定，忠实履行独立董事的 职责，谨慎、认真、勤勉地行使公司所赋予独立董事的权利，积极出席公司相关 会议，认真审议各项议案，对公司的相关事项发表了独立意见，较好地维护了公 司和股东特别是中小股东的合法权益。现就本人 2024 年度履行职责情况述职如 下： 一、独立董事基本情况 本人李群英，女，1981 年 2 月出生，中国国籍，无境外永久居留权，民商法 专业硕士，执业律师。2005 年至 2006 年，任河南邮政职员；2006 年至 2010 年， 任昆山华德宝科盈扶梯设备有限公司人事行政经理；2010 年至 2013 年，任昆山 柯斯美光电有限公司副总经理；2021 年 4 月至今，任上海合鸿律师事务所创始 合伙人。2019 年 3 月至今，任亚香股份独立董事，本人未在公司担任除独立董 事外的其他职务。 二、是否存在影响独立性的情况说明 作为公司独立董事， ...

Financial Performance - The company's operating revenue for 2024 reached ¥796,682,291.89, representing a 26.42% increase compared to ¥630,177,917.19 in 2023[20]. - The net profit attributable to shareholders decreased by 30.51% to ¥55,702,989.79 in 2024 from ¥80,158,022.75 in 2023[20]. - The cash flow from operating activities net amount was ¥31,323,296.98, down 58.75% from ¥75,931,894.12 in the previous year[20]. - Basic earnings per share fell by 31.00% to ¥0.69 in 2024, compared to ¥1.00 in 2023[20]. - Total assets increased by 14.44% to ¥2,104,809,521.16 at the end of 2024, up from ¥1,839,185,281.42 at the end of 2023[20]. - The company reported a decrease in the weighted average return on net assets to 3.47% in 2024 from 5.11% in 2023, a decline of 1.64%[20]. - The gross profit margin for the flavor and fragrance manufacturing segment was 25.52%, down 6.65% from the previous year[82]. - The company achieved a total revenue of ¥796,682,291.89 in 2024, representing a year-on-year growth of 26.42%[80]. - The net profit attributable to shareholders was ¥55,702,989.79, a decrease of 30.51% compared to the previous year, primarily due to intensified product price competition[72]. Dividend and Capital Increase - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on a total of 79,927,100 shares[3]. - The company will increase its capital reserve by converting 4 shares for every 10 shares held by shareholders[3]. - The total cash dividend, including other methods, accounts for 100% of the total profit distribution amount[187]. - The company will also increase its capital stock by 4 shares for every 10 shares held, resulting in a total capital increase of 31,970,840 shares[189]. Market and Industry Outlook - The company plans to expand its market presence, targeting a revenue growth in the fragrance and flavor industry, projected to reach ¥50 billion by 2025[30]. - The global flavor and fragrance market size reached approximately $30.6 billion in 2023, with a year-on-year growth of 2.3%, and is expected to increase to $32.1 billion by 2025[38]. - The Chinese flavor and fragrance industry market size was about 43.9 billion yuan in 2023, reflecting a year-on-year growth of 2.6%, and is projected to exceed 50 billion yuan by 2026[40]. - The industry is experiencing a trend of increasing demand driven by rising consumer income and preferences for diverse and healthy products[37]. - The young consumer demographic (ages 18-35) in China, approximately 550 million strong, is driving demand for unique and high-quality fragrance products, influencing market diversification[50]. Research and Development - The company is focusing on research and development of new products to enhance its competitive edge in the fragrance industry[30]. - The company has developed over 310 products across three main series: natural flavors, synthetic flavors, and cooling agents, establishing a strong market presence[54]. - The company has achieved ISO9001:2015 and ISO22000:2018 certifications, ensuring high-quality standards and food safety compliance for its products[57]. - The company holds 3 authorized patents for Isopentyl Acetate and has a dedicated R&D center to ensure market-driven innovation[62]. - The company has 7 authorized patents for WS-23, with a strong emphasis on project-based R&D management to align innovations with market needs[62]. Risk Management - The report emphasizes the importance of risk awareness regarding forward-looking statements related to future plans and performance forecasts[3]. - The company has outlined potential risks in its future development outlook section[3]. - The supply of natural raw materials for the flavor and fragrance industry is subject to climate conditions and ecological protection policies, leading to potential instability[35]. Corporate Governance - The company has a total of 9 board members, including 3 independent directors, complying with legal and regulatory requirements[132]. - The company has implemented a strict financial accounting system, enabling independent financial decision-making without shared bank accounts with the controlling shareholder[140]. - The company has maintained a transparent information disclosure process, ensuring all shareholders have equal access to information[136]. - The company has established a sound internal management structure, ensuring independent exercise of management authority[141]. Employee and Management - The total number of employees at the end of the reporting period is 719, with 166 in the parent company and 553 in major subsidiaries[180]. - The professional composition includes 400 production personnel, 132 technical personnel, and 21 sales personnel[180]. - The company emphasizes employee training and development, implementing a systematic training program that includes both pre-job and on-the-job training[183]. Strategic Initiatives - The company plans to implement a matrix marketing network and improve customer service responsiveness to enhance market share and customer satisfaction[1][2]. - The company is considering future refinancing options, including issuing stocks or bonds, to meet its development needs while managing financial risks[1][2]. - The company plans to invest in the production of flavoring agents and food additives, with a target capacity of 6,500 tons per year[112].

亚香股份（301220）公告，2024年营业收入7.97亿元，同比增长26.42%。归属于上市公司股东的净利润 5570.3万元，同比下降30.51%。公司拟向全体股东每10股派发现金红利2元(含税)，送红股0股(含税)， 以资本公积金向全体股东每10股转增4股。 ...

化工板块反复活跃 红墙股份3连板 智通财经4月21日电，红墙股份、尤夫股份走出3连板，中毅达走出8天4板，亚香股份、丹化科技、山东 海化、江天化学等涨幅靠前。消息面上，截至4月17日，A股共有31家化工上市公司披露一季度业绩预 告，全部预喜，其中21家预增。整体来看，产品价格上涨、结构优化等是化工行业上市公司一季度取得 较好业绩的主要因素。 ...

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]